CJC-1295 DAC dosage chart
5 mg Vial
CJC-1295 DAC is dosed at 300 mcg–1 mg weekly via subcutaneous injection in educational protocols. A 5 mg vial reconstituted with bacteriostatic water yields about 2.5 mg/mL. This information is for research and educational use only.
- Reconstitute
- Add 2.0 mL bacteriostatic water → 2.5 mg/mL (2500 mcg/mL) concentration.
- Typical dose range
- 300–1000 mcg per injection, twice weekly (gradual titration).
- Easy measuring
- At 2.5 mg/mL, 1 unit = 0.01 mL = 25 mcg on a U-100 insulin syringe.
- Storage
- Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Dosing schedule
| Week | Per-Injection Dose (mcg) | Units (per injection) (mL) | Weekly Total |
|---|---|---|---|
| Weeks 1–2 | 300 mcg (0.3 mg) | 12 units (0.12 mL) | 600 mcg/week |
| Weeks 3–4 | 500 mcg (0.5 mg) | 20 units (0.20 mL) | 1000 mcg/week |
| Weeks 5–6 | 750 mcg (0.75 mg) | 30 units (0.30 mL) | 1500 mcg/week |
| Weeks 7–12 | 1000 mcg (1 mg) | 40 units (0.40 mL) | 2000 mcg/week |
Reconstitution steps
- 1Draw 2.0 mL bacteriostatic water with a sterile syringe.
- 2Inject slowly down the vial wall; avoid foaming.
- 3Gently swirl/roll until dissolved (do not shake).
- 4Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Important Notes
Practical considerations for consistency and safety.
- Use new sterile insulin syringes; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document each dose, injection site, and timing to maintain consistency.
- The DAC modification provides sustained release; maintain consistent twice-weekly scheduling.
- The 5 mg vial provides more doses per vial, reducing reconstitution frequency.
How This Works
CJC-1295 DAC mimics endogenous GHRH, binding to GHRH receptors on pituitary somatotrophs to drive GH release. The DAC modification (albumin-binding moiety) keeps the GHRH analog circulating for days rather than minutes, extending the half-life to approximately 6–8 days. The resulting GH surge stimulates IGF-1 production (primarily in the liver); IGF-1 then mediates many growth and metabolic effects through JAK/STAT signaling pathways. Notably, pulsatile GH secretion persists even during continuous CJC-1295 stimulation, preserving physiological release patterns.
Potential Benefits & Side Effects
Observations from preclinical and clinical literature.
- Supports sustained elevation of GH and IGF-1 in a dose-dependent manner.
- May promote increased lean body mass, reduced fat mass, and improved body composition consistent with GH/IGF-1 axis activation.
- Enhanced protein synthesis and recovery potential through anabolic signaling.
- Generally well tolerated in clinical studies; occasional mild injection-site reactions (redness, swelling) may occur.
- Some individuals report transient flushing, headache, or water retention during initial titration.
Lifestyle Factors
Complementary strategies for best outcomes.
- Pair with a balanced, protein-forward diet tailored to energy and recovery needs.
- Combine resistance training and aerobic activity to reinforce GH-mediated adaptations.
- Prioritize quality sleep (7–9 hours) as endogenous GH release peaks during deep sleep.
- Manage stress to support hormonal balance and adherence.
Injection Technique
General subcutaneous guidance from clinical best-practice resources.
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
- Do not aspirate for subcutaneous injections; inject slowly and steadily.
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
- Do not rub or massage the injection site after administration.
important-note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.
CJC-1295 DAC dosage FAQs
How much bacteriostatic water do you use to reconstitute CJC-1295 DAC?
Add 2.0 mL bacteriostatic water → 2.5 mg/mL (2500 mcg/mL) concentration. for a 5 mg Vial vial. Add the water slowly against the inside wall of the vial and swirl — never shake — until the powder fully dissolves.
What is a typical CJC-1295 DAC dose?
Typical dose range: 300–1000 mcg per injection, twice weekly (gradual titration).. Figures are research reference values only.
What does the CJC-1295 DAC dosing schedule look like?
Weeks 1–2 — 300 mcg (0.3 mg) — 12 units (0.12 mL) — 600 mcg/week; Weeks 3–4 — 500 mcg (0.5 mg) — 20 units (0.20 mL) — 1000 mcg/week; Weeks 5–6 — 750 mcg (0.75 mg) — 30 units (0.30 mL) — 1500 mcg/week; Weeks 7–12 — 1000 mcg (1 mg) — 40 units (0.40 mL) — 2000 mcg/week. The full table above lists every step with matching syringe units.
What are the mixing steps for CJC-1295 DAC?
Draw 2.0 mL bacteriostatic water with a sterile syringe. Inject slowly down the vial wall; avoid foaming. Gently swirl/roll until dissolved (do not shake).
How should reconstituted CJC-1295 DAC be stored?
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles..
How many insulin syringe units equal a CJC-1295 DAC dose?
Units depend on the water volume you used. Divide your target dose by the vial concentration to get millilitres, then multiply by 100 — 1 unit on a U-100 insulin syringe is 0.01 mL. The Spartan Peptides reconstitution calculator does this conversion for you.
Is CJC-1295 DAC approved for human use?
No. CJC-1295 DAC is sold and referenced strictly as a research chemical. Nothing on this page is medical advice and the material is not for human consumption.
Educational and research information only. Not medical advice, not for human consumption. Values are reference figures — always verify your own math with the reconstitution calculator.
On any insulin syringe, 1 unit = 0.01 mL, so unit counts above hold across brands.